Published in PLoS One on December 21, 2011
Data-driven prediction of drug effects and interactions. Sci Transl Med (2012) 2.93
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov (2013) 2.46
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today (2013) 1.24
Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics (2012) 1.22
A survey of current trends in computational drug repositioning. Brief Bioinform (2015) 1.18
TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J (2013) 1.11
Recycling side-effects into clinical markers for drug repositioning. Genome Med (2012) 0.99
A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case. BMC Syst Biol (2015) 0.99
Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA Annu Symp Proc (2014) 0.89
Compensating for literature annotation bias when predicting novel drug-disease relationships through Medical Subject Heading Over-representation Profile (MeSHOP) similarity. BMC Med Genomics (2013) 0.89
In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med (2016) 0.85
Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects. Sci Rep (2015) 0.85
Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data. PLoS One (2013) 0.85
Construction of drug network based on side effects and its application for drug repositioning. PLoS One (2014) 0.84
Systematic prediction of drug combinations based on clinical side-effects. Sci Rep (2014) 0.84
Computational drug repositioning through heterogeneous network clustering. BMC Syst Biol (2013) 0.84
Drug repositioning for diabetes based on 'omics' data mining. PLoS One (2015) 0.83
Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics (2014) 0.82
An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations. PLoS One (2016) 0.81
A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors. Pac Symp Biocomput (2013) 0.81
Exploring the relationship between drug side-effects and therapeutic indications. AMIA Annu Symp Proc (2013) 0.80
Integrative relational machine-learning for understanding drug side-effect profiles. BMC Bioinformatics (2013) 0.80
Mining integrated semantic networks for drug repositioning opportunities. PeerJ (2016) 0.80
A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs. Bioinformation (2013) 0.79
A phenome-guided drug repositioning through a latent variable model. BMC Bioinformatics (2014) 0.78
A chemo-centric view of human health and disease. Nat Commun (2014) 0.78
Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events. J Med Internet Res (2016) 0.78
Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties. Sci Rep (2016) 0.76
Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space. Comput Math Methods Med (2015) 0.76
Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory. BMC Bioinformatics (2016) 0.76
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology (2016) 0.76
Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures. PLoS One (2016) 0.76
DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome. Sci Rep (2016) 0.75
Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining. PLoS One (2016) 0.75
Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics (2010) 26.76
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Drug target identification using side-effect similarity. Science (2008) 9.24
Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A (2010) 4.35
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther (2011) 3.50
Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol (2010) 3.23
PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol (2011) 3.22
PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet (2007) 2.65
Human disease-drug network based on genomic expression profiles. PLoS One (2009) 2.62
Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis (2006) 2.47
Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med (2008) 2.44
Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model (2006) 1.95
Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin Pharmacol Ther (2009) 1.86
In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comput Biol (2007) 1.40
Management of peripheral arterial disease in primary care. BMJ (2003) 1.37
Drug repositioning for orphan diseases. Brief Bioinform (2011) 1.37
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology (2006) 1.27
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. PLoS Comput Biol (2011) 1.26
Predicting adverse drug reactions using publicly available PubChem BioAssay data. Clin Pharmacol Ther (2011) 1.24
DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res (2011) 1.23
Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol (2009) 1.18
Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis (1999) 1.12
SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res (2009) 1.10
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One (2010) 1.10
A CitationRank algorithm inheriting Google technology designed to highlight genes responsible for serious adverse drug reaction. Bioinformatics (2009) 1.02
Immunological consequences of ischemic stroke: immunosuppression and autoimmunity. J Neuroimmunol (2010) 1.00
Erythropoietic and hepatic porphyrias. J Inherit Metab Dis (2000) 1.00
Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety (2011) 0.97
Computational prediction of human drug metabolism. Expert Opin Drug Metab Toxicol (2005) 0.97
Investigations of cardiovascular 5-hydroxytryptamine receptor subtypes in the rat. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.95
Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience (2011) 0.92
The role of translational bioinformatics in drug discovery. Drug Discov Today (2011) 0.91
Intracranial hypotension as a cause of radiculopathy from cervical epidural venous engorgement: case report. AJNR Am J Neuroradiol (2002) 0.88
Vascular thrombin receptor regulation in hypertensive rats. Circ Res (1997) 0.87
Classification and treatment of tardive syndromes. Neurologist (2003) 0.86
Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology (Berl) (2010) 0.86
Over-the-counter analgesics normalize blood glucose and body composition in mice fed a high fat diet. Biochem Pharmacol (2008) 0.86
Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol (2000) 0.84
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate (2009) 0.83
Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin. J Physiol Biochem (2011) 0.82
Positive school and classroom environment: precursors of successful implementation of positive youth development programs. ScientificWorldJournal (2008) 0.81
Sexual dysfunction due to antihypertensive agents. Drug Intell Clin Pharm (1984) 0.81
Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol (Oxf) (2007) 0.80
PPARgamma Agonists: Blood Pressure and Edema. PPAR Res (2009) 0.80
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J Clin Psychiatry (2005) 0.79
Complaints of cold extremities among patients on antihypertensive treatment. Acta Med Scand (1983) 0.79
Effect of diabetes on porphyric attacks. Br Med J (Clin Res Ed) (1987) 0.78
Effects of diabetes mellitus on patients with acute intermittent porphyria. J Intern Med (1999) 0.78
PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner. Eur J Pharmacol (2009) 0.78
Statins: cholesterol, blood pressure and beyond. J Hypertens (2002) 0.78
Matrix metalloproteinase-8 and the regulation of blood pressure, vascular inflammation, and atherosclerotic lesion growth. Circ Res (2009) 0.77
Sinus arrest associated with clonidine therapy. Clin Cardiol (1988) 0.77
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Comparative gene prediction in human and mouse. Genome Res (2003) 4.13
Comparison of mouse and human genomes followed by experimental verification yields an estimated 1,019 additional genes. Proc Natl Acad Sci U S A (2003) 3.73
Human disease-drug network based on genomic expression profiles. PLoS One (2009) 2.62
Use of genome-wide association studies for drug repositioning. Nat Biotechnol (2012) 2.51
A global pathway crosstalk network. Bioinformatics (2008) 2.27
Inferring pathways from gene lists using a literature-derived network of biological relationships. Bioinformatics (2004) 1.92
A pathway-based view of human diseases and disease relationships. PLoS One (2009) 1.52
Correcting timolol prescribing in glaucoma management. Eur J Ophthalmol (2015) 1.07
Novelty in the target landscape of the pharmaceutical industry. Nat Rev Drug Discov (2013) 1.03
Removal of broken Kuntscher's nail: an innovative close technique. J Trauma (2005) 1.02
Gene Vector Analysis (Geneva): a unified method to detect differentially-regulated gene sets and similar microarray experiments. BMC Bioinformatics (2008) 0.91
Evaluation of analytical methods for connectivity map data. Pac Symp Biocomput (2013) 0.91
Role of oral exfoliative cytology in predicting premalignant potential of oral submucous fibrosis: A short study. J Cancer Res Ther (2015) 0.90
Electronic health records: Implications for drug discovery. Drug Discov Today (2011) 0.87
Inferential ecosystem models, from network data to prediction. Ecol Appl (2011) 0.85
Primary pituitary tubercular abscess mimicking as pituitary adenoma. Indian J Endocrinol Metab (2011) 0.82
A novel approach applying a chemical biology strategy in phenotypic screening reveals pathway-selective regulators of histone 3 K27 tri-methylation. Mol Biosyst (2014) 0.80
Reliability of toluidine blue vital staining in detection of potentially malignant oral lesions--time to reconsider. Asian Pac J Cancer Prev (2011) 0.79
Reply to Rational drug repositioning by medical genetics. Nat Biotechnol (2013) 0.78
Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism. Mov Disord (2012) 0.77
Computational identification of transcription factors involved in early cellular response to a stimulus. J Bioinform Comput Biol (2005) 0.76
A young diabetic with suicidal risk: Rare disease with a rarer presentation. Indian J Endocrinol Metab (2013) 0.75
Exploring the foundation of genomics: a northern blot reference set for the comparative analysis of transcript profiling technologies. Comp Funct Genomics (2004) 0.75
Oral tuberculosis following successful treatment of oral malignancy. J Cancer Res Ther (2013) 0.75
Drug repositioning from the combined evaluation of phenotypic and target-based screening. AMIA Jt Summits Transl Sci Proc (2013) 0.75
Innovative healthcare delivery model to expand access and outreach of cancer care services. J Cancer Res Ther (2016) 0.75
Impact of genetically supported target selection on R&D productivity. Nat Rev Drug Discov (2016) 0.75
Substance P concentration in human amniotic membrane. Arch Ophthalmol (2012) 0.75
Oral anticoagulant therapy. Indian J Dent Res (2013) 0.75
Psychiatric expertise for a multidisciplinary Huntington's disease clinic. Psychiatr Serv (2009) 0.75
Twenty-two year follow-up of an Indian family with dysferlinopathy-clinical, immunocytochemical, western blotting and genetic features. Neurol India (2008) 0.75